Androgens and Anabolic Steroids: Pharmacology, Testosterone Therapy and Safety

Evidence and references reviewed: 10 November 2026.

Androgen pharmacology spans normal reproductive physiology, treatment of hormone deficiency and the harms of nonmedical anabolic-steroid use. Understanding the distinction between physiological replacement and supraphysiological exposure is essential when interpreting efficacy and safety evidence.

Testosterone and its active metabolites

Testosterone is the principal secreted androgen in men, produced mainly by testicular Leydig cells under luteinising hormone stimulation. Testosterone also occurs in women; its precursors can undergo peripheral conversion. Hormone concentration must therefore be interpreted in its physiological and clinical context.1

Testosterone and dihydrotestosterone bind the intracellular androgen receptor, a transcription factor that regulates responsive genes. The enzyme 5α-reductase converts testosterone to dihydrotestosterone, which binds the receptor more strongly. Aromatase converts testosterone to estradiol. Some skeletal effects therefore involve estrogen signalling as well as direct androgen action.2

Androgen receptor pharmacodynamics and endocrine feedback

The androgen receptor (AR) is a ligand-regulated nuclear transcription factor. After testosterone or dihydrotestosterone binds, receptor-associated signaling changes expression of androgen-responsive genes. Outcomes depend on tissue, receptor context, hormone concentration and androgen metabolism. Dihydrotestosterone (DHT) is especially important in tissues with substantial 5α-reductase activity, while conversion of testosterone to estradiol by aromatase contributes to bone and other physiological effects.1,2

Exogenous androgens suppress the hypothalamic–pituitary–gonadal axis through negative feedback, lowering GnRH, luteinising hormone (LH) and follicle-stimulating hormone (FSH). Consequently, prescribed testosterone can suppress intratesticular testosterone and sperm production even when serum testosterone appears normal. Patients seeking fertility require specialist counseling before treatment rather than assuming testosterone replacement helps conception.5

Formulation determines pharmacokinetics

Injectable esters prolong delivery by slowing release from an oily depot. For example, the cited testosterone cypionate label gives an approximate intramuscular half-life of eight days. This value cannot be transferred to every testosterone preparation. Serum concentration timing, dosing intervals and monitoring must match the specific product.3

Transdermal gel provides a different delivery system. Unintentional skin transfer can virilise children or other contacts; the cited 1.62% gel carries a boxed warning about secondary exposure. Users must follow its application, handwashing, covering and washing-before-contact instructions. Formulations and concentrations should not be assumed to be dose-interchangeable.4

Comparing formulations without assuming dose equivalence

Formulation Pharmacokinetic feature Key safety or practical issue
Intramuscular testosterone esters Release after injection from a depot; peaks and troughs depend on ester and formulation. Correct dose interval and blood sampling time are formulation-specific; erythrocytosis can occur.
Transdermal gel Daily skin absorption, with gradual systemic delivery. Secondary transfer to others, skin instructions and product-specific labeling.
Transdermal patch Continuous delivery through skin. Potential local skin irritation; not interchangeable with gel by milligram content.
Selected oral testosterone products Absorption depends on product formulation and food-related conditions. May have product-specific blood-pressure warnings and monitoring requirements.
Subcutaneous delivery or implants Product-dependent sustained delivery and variable administration setting. Procedural, local adverse-effect and retrieval considerations.

Products differ in bioavailability, absorption, peak/trough pattern and approved routes. A milligram amount from one formulation must not be converted directly to another without the prescribing label and a knowledgeable clinician. Injections, gels and other delivery systems also require different timing of serum testosterone testing.3,4

Establish the indication before prescribing

The Endocrine Society recommends diagnosing male hypogonadism from compatible symptoms and consistently low testosterone, confirmed with a repeat morning fasting measurement. LH and FSH help distinguish testicular from hypothalamic–pituitary causes. Fatigue alone or one isolated low result is insufficient. Treatment goals and fertility plans should be discussed before starting therapy.5

The cited product label covers testosterone replacement for specified deficient states; it also warns about impaired spermatogenesis. Exogenous testosterone is not a fertility treatment and can reduce sperm production. Pregnancy exposure can cause fetal harm.4

Distinguish replacement from nonmedical anabolic-steroid exposure

Physiological testosterone replacement aims to restore appropriate concentrations in a patient with an established indication, while nonmedical anabolic-androgenic steroid (AAS) use often involves exposure beyond normal physiology and sometimes undisclosed combinations of substances. These contexts have different populations, exposure levels, monitoring and risks. Results from clinical replacement trials cannot establish safety for bodybuilding or performance-enhancement regimens.7,11

Potential consequences of nonmedical use include infertility, testicular atrophy, acne, androgenic hair loss, gynecomastia, mood changes, adverse lipid profiles, hypertension, erythrocytosis and cardiovascular complications. Some people experience dependence and significant depressive symptoms during withdrawal. Patients should receive nonjudgmental clinical assessment, including cardiovascular and reproductive history, rather than being advised to undertake unsupervised hormonal “post-cycle therapy.”10,11

Anabolic steroids and liver toxicity

Chemical modifications influence delivery and toxicity. Prolonged high-dose exposure, particularly to 17α-alkylated androgens, has been associated with cholestatic and serious hepatic injury, including hepatic tumours and peliosis hepatis. These risks should not be generalised as an identical hepatic profile for every formulation, nor should oral anabolic products be presented as harmless alternatives to injections.3

Historical indications do not establish current approval. FDA determined that Oxandrin (oxandrolone) had been withdrawn for safety or effectiveness reasons; an October 2026 correction explicitly included referencing generic applications. Availability and approved uses must be checked by jurisdiction.6

Cardiovascular evidence: what TRAVERSE showed

TRAVERSE randomised 5,246 men aged 45–80 with symptomatic hypogonadism, repeatedly low testosterone and established or high cardiovascular risk to testosterone gel or placebo. Major cardiovascular events occurred in 7.0% versus 7.3%; the hazard ratio was 0.96 (95% CI 0.78–1.17), meeting the trial’s noninferiority criterion. Atrial fibrillation, acute kidney injury and pulmonary embolism occurred more often in the testosterone group.7

This supports a bounded conclusion about the studied population and replacement regimen. It does not establish lifelong safety, benefit for everyone with tiredness, or safety of high-dose bodybuilding combinations.7

How to interpret cardiovascular trial results correctly

TRAVERSE studied men with documented symptomatic low testosterone who were prescribed a specific transdermal testosterone regimen. Its major adverse cardiovascular event results met the trial’s noninferiority criterion, but do not prove that treatment improves cardiovascular outcomes. More atrial fibrillation, pulmonary embolism and acute kidney injury were observed among testosterone recipients. Trial findings also do not cover supraphysiological AAS use or everyone with fatigue and normal testosterone.7

FDA’s February 2025 class-wide update removed selected boxed-warning language about cardiovascular events after evaluating TRAVERSE, while requiring additional blood-pressure information. The later June 2026 requested label changes about age-related deficiency and prostate conditions must still be distinguished from the latest legally effective product-specific labeling; clinicians should consult the current label for the exact formulation.8,9

FDA changes in 2025 and requested revisions in 2026

In February 2025, FDA requested removal of boxed-warning language about increased adverse cardiovascular outcomes and added or strengthened blood-pressure warnings following ambulatory monitoring studies. This was not removal of every warning associated with testosterone products.8

In June 2026, HHS/FDA announced requested revisions addressing the age-related hypogonadism limitation and prostate-related information. The announcement proposed narrowing the prostate-cancer contraindication to metastatic disease, while retaining assessment and monitoring and acknowledging limits in long-term evidence. It also addressed uncertainty in severe urinary symptoms.9

These were requested changes. The gel label cited here, revised January 2026, predates that announcement and retains older prostate language. Clinicians should verify the latest label for the exact product and seek appropriate specialist advice for prostate disease; a policy announcement is not a substitute for that review.4,9

Monitoring and interactions

Assess symptom response, testosterone and haematocrit after initiation and periodically thereafter. The Endocrine Society recommends baseline haematocrit, reassessment at three to six months and ongoing monitoring; a value above 54% warrants interruption and evaluation before restarting at a reduced dose. Prostate monitoring should follow individual risk and shared decisions. Elevated haematocrit, untreated severe sleep apnoea and recent major cardiovascular events require particular assessment.5

Monitor blood pressure as well.8 Androgens may alter anticoagulant effects, requiring closer INR checks with warfarin; they may lower insulin requirements. Concurrent corticosteroids can increase fluid retention. These documented interactions are more useful than assuming all androgen products share one CYP-based interaction rule.4

Practical monitoring checklist for prescribed replacement

Parameter Why it matters Clinical principle
Symptoms and signs Confirm meaningful response rather than treating a laboratory value alone. Review sexual function, energy, adverse effects and other causes of symptoms.
Serum testosterone Assess exposure and prevent sustained under- or overreplacement. Sample at the formulation-specific time and apply the label/guideline target.
Hematocrit Detect androgen-related erythrocytosis. Check before and after starting; above 54% warrants holding treatment and evaluation per guideline.5
Blood pressure Some testosterone products can raise BP. Monitor and address new/worsening hypertension.8
Prostate/urinary evaluation Identify symptoms, personal cancer risks and applicable screening decisions. Interpret in light of current product label and patient-specific risk, not obsolete blanket rules.
Sleep apnea and fluid retention May affect safety and treatment suitability. Assess severe untreated sleep apnea, edema and cardiovascular comorbidity.
Fertility planning External testosterone suppresses spermatogenesis. Discuss before initiation; arrange reproductive specialist review when needed.

Initial and follow-up schedules depend on medicine, patient and country. A single normal testosterone result does not exclude treatment-related erythrocytosis, hypertension or sleep-related complications. Therapy should be periodically reassessed for sustained benefit and tolerability.

SARMs and nonmedical use

Selective androgen receptor modulators marketed for bodybuilding are not FDA-approved alternatives to testosterone treatment. FDA reports serious liver injury and warns of cardiovascular, reproductive and psychiatric risks. A “research use” label does not establish product quality or human safety.10

Anabolic-steroid use can lead to dependence. Withdrawal may involve fatigue, sleep disruption, reduced libido and depression. People who are using these products should seek clinical help for cessation and associated health problems rather than rely on unregulated “post-cycle” regimens.11

Sound prescribing connects a verified indication, formulation-specific dosing and monitoring with a realistic discussion of benefit and harm. Neither a generic steroid warning nor a broad claim of safety captures that decision.

Frequently asked questions

Is testosterone the same as an anabolic steroid?

Testosterone is an endogenous androgen with anabolic effects and is also a prescription medicine. Nonmedical anabolic-steroid use often involves different agents or supraphysiological exposure with higher risks.

Can prescribed testosterone reduce fertility?

Yes. Exogenous androgens suppress gonadotropins and sperm production, so fertility goals must be discussed before prescribing.5

Did TRAVERSE prove all androgen use is safe for the heart?

No. It studied a defined replacement population and regimen and cannot be generalized to bodybuilding cycles or indefinite use.7

Did FDA remove every cardiovascular warning in 2025?

No. The FDA changed selected boxed-warning language but emphasized product-specific blood-pressure effects.8

Are SARMs approved alternatives for building muscle?

No. Products marketed for bodybuilding can carry significant liver, cardiovascular and reproductive risks.10

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023. Chapter 49: Androgens and the male reproductive tract. Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=3191&sectionid=267775126
  2. National Cancer Institute. Therapeutic testosterone. NCI Drug Dictionary [Internet]. [cited 2026 Nov 9]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/therapeutic-testosterone
  3. DailyMed. Testosterone cypionate injection, USP: prescribing information [Internet]. [cited 2026 Nov 9]. Available from: https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setId=108facca-c6d2-48fa-ba48-667c9498c61b
  4. DailyMed. Testosterone gel 1.62%: prescribing information [Internet]. Revised 2026 Jan [cited 2026 Nov 9]. Available from: https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61387416-510d-40c5-9e2d-24bfb7f56d08
  5. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-44. doi:10.1210/jc.2018-00229. Available from: https://doi.org/10.1210/jc.2018-00229
  6. US Food and Drug Administration. Determination that Oxandrin (oxandrolone) tablets, 2.5 milligrams and 10 milligrams, were withdrawn from sale for reasons of safety or effectiveness; correction. Federal Register. 2026 Oct 7;91:64154. Available from: https://www.govinfo.gov/app/details/FR-2026-10-07/2026-20503
  7. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389:107-17. doi:10.1056/NEJMoa2215025. Available from: https://pubmed.ncbi.nlm.nih.gov/37326322/
  8. US Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products [Internet]. 2025 Feb 28 [cited 2026 Nov 9]. Available from: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-class-wide-labeling-changes-testosterone-products
  9. US Department of Health and Human Services. HHS announces requested updates to testosterone therapy product labels [Internet]. 2026 Jun 18 [cited 2026 Nov 9]. Available from: https://www.hhs.gov/press-room/fda-requests-updates-testosterone-therapy-labeling.html
  10. US Food and Drug Administration. Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more [Internet]. [cited 2026 Nov 9]. Available from: https://www.fda.gov/drugs/fraudulent-products/certain-bodybuilding-products-put-consumers-risk-heart-attack-stroke-serious-liver-damage-and-more
  11. National Library of Medicine. Anabolic steroids. MedlinePlus [Internet]. [cited 2026 Nov 9]. Available from: https://medlineplus.gov/anabolicsteroids.html

⚠️ Medical Disclaimer

This article is intended for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this article.

The information provided here is based on current scientific literature and established pharmacological principles. However, medical knowledge evolves continuously, and individual patient responses to medications may vary. Healthcare professionals should always use their clinical judgment when applying this information to patient care.

Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *